Liposome‐encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre‐treated with anthracyclines
Hematological Oncology2007Vol. 25(4), pp. 198–203
Citations Over TimeTop 11% of 2007 papers
Luigi Rigacci, Silvia Mappa, Luca Nassi, Renato Alterini, Valentina Carrai, Franco Bernardi, Alberto Bosi
Abstract
The replacement of doxorubicin with its non-pegylated liposomal pharmaceutical analogue was well tolerated and highly effective in inducing remission in this group of patients at high risk for cardiac toxicity or previously treated with anthracyclines. Its high tolerability and low incidence of cardiac events (only one patient) warrants further studies to confirm the clinical benefits of liposomal doxorubicin in this subset of patients.
Related Papers
- → Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs(2002)93 cited
- [Cardiotoxicity of conservative treatment of solid tumors].(2012)
- → Vincristine, prednisone, and daunomycin in acute leukemia of childhood.Writing committee(1971)24 cited
- Anthracycline-induced cardiotoxicity, a pathophysiology based approach for early detection and protective strategies(2012)